zoledronic acid has been researched along with prednisolone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A | 1 |
| Brendel, C; Hamann, C; Hofbauer, LC; Krüger, A; Neubauer, A; Ramaswamy, A; Schnabel, M | 1 |
| Aoyama, M; Hirayama, Y; Ito, Y; Kanamaru, T; Kawamura, M; Nakamura, N; Sonoda, T | 1 |
| Apalla, Z; Lallas, A; Lefaki, I; Sotiriou, E; Tzellos, T | 1 |
| Iida, S | 1 |
| Almeida, DR; Belliveau, MJ; Urton, TE | 1 |
| Suzuki, K | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Moser, F; Sterki Novakova, K; Tamborrini, G | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Akyuz, G; Ata, P; Delil, K; Gencer-Atalay, K; Ozgen, Z; Ozturk, EC; Yagci, I | 1 |
| George, DJ | 1 |
| Bratt, O; Carlsson, S; Fransson, P; Karlsson, CT; Kindblom, J; Stranne, J | 1 |
5 review(s) available for zoledronic acid and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Challenges in the treatment of fibrodysplasia ossificans progressiva.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density Conservation Agents; Breathing Exercises; Cushing Syndrome; Female; Humans; Indomethacin; Muscle Stretching Exercises; Myositis Ossificans; Physical Therapy Modalities; Prednisolone; Radiotherapy; Range of Motion, Articular; Risedronic Acid; Vitamin D; Young Adult; Zoledronic Acid | 2019 |
2 trial(s) available for zoledronic acid and prednisolone
| Article | Year |
|---|---|
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Diphosphonates; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Zoledronic Acid | 2008 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
11 other study(ies) available for zoledronic acid and prednisolone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multimodal therapy for vertebral involvement of systemic mastocytosis.
Topics: Adult; Back Pain; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Histamine; Humans; Hypotension; Imidazoles; Male; Mast Cells; Mastocytosis, Systemic; Osteoporosis; Postoperative Complications; Prednisolone; Pressure; Proto-Oncogene Proteins c-kit; Spinal Fractures; Spine; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2009 |
[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Diphosphonates; Estramustine; Fatal Outcome; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2011 |
Possible zoledronic acid-induced dermatomyositis.
Topics: Aged; Anti-Inflammatory Agents; Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Female; Humans; Imidazoles; Prednisolone; Treatment Outcome; Zoledronic Acid | 2012 |
Acute anterior uveitis following zoledronic acid infusion for osteoporosis.
Topics: Acute Disease; Blood Sedimentation; Bone Density Conservation Agents; C-Reactive Protein; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Ointments; Osteoporosis, Postmenopausal; Parasympatholytics; Prednisolone; Tropanes; Uveitis, Anterior; Visual Acuity; Zoledronic Acid | 2012 |
Topics: Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Ophthalmic Solutions; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prednisolone; Uveitis, Anterior; Zoledronic Acid | 2018 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Denosumab; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sweden; Zoledronic Acid | 2022 |